Nephros Inc

Nephros, Inc. is a medical device company, which engages in developing and selling liquid purification filters and an on-line mid dilution hemodiafiltration system. The company operates in two segments: Water Filtration, Pathogen Detection and Renal Products. The Water Filtration segment includes both the medical device and commercial filtration product lines. The Pathogen Detection segment develops and sells portable, real-time water testing systems designed to provide actionable data on waterborne pathogens in approximately one hour. The Renal Products segment consists of SRP, which is focused on the development of medical device products for patients with renal disease, including a second-generation HDF system for the treatment of patients with ESRD. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water, bicarbonate concentrate, and blood. The company was founded on April 3, 1997 and is headquartered in South Orange, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Nephros Inc reports first profitable quarter, eyes growth opportunities

Nephros Inc delivered a strong performance in Q3 2024, achieving profitability and operational efficiency gains.
While facing revenue challenges and liquidity concerns, the company's strategic initiatives and focus on financial discipline position it for growth.
Opportunities in new markets and customer engagement through digital tools provide avenues for future expansion.
Balancing growth pursuits with financial prudence will be crucial for Nephros Inc's sustained success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nephros, Inc. (NEPH) CEO Andy Astor on Q1 2021 Results - Earnings Call Transcript

Nephros Inc. (NEPH) delivered earnings and revenue surprises of 57.14% and 1.33%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Nephros Inc. (NEPH) Reports Q1 Loss, Tops Revenue Estimates

Net Revenue of $2.7 Million; Highest First Quarter in Company History

Nephros Announces Results for Quarter Ended March 31, 2021

SOUTH ORANGE, NJ, April 26, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nephros , Inc. (Nasdaq: NEPH), a leading water technology company, today announced that it will file its first quarter financial results on Thursday, May 6, 2021 after market close and will host a conference call that same day at 4:30 PM ET.

Nephros Announces First Quarter 2021 Financial Results Conference Call

The stock price of Nephros (NASDAQ: NEPH) increased by 21.63% today. This is why it happened.

Nephros Stock Price Increased 21.63%: Why It Happened

Anticipates Net Revenue of $2.7 Million; Highest First Quarter in Company History

Nephros Announces Preliminary Results for First Quarter of 2021

SOUTH ORANGE, N.J., March 16, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced that Andy Astor, Chief Executive Officer, has been invited to present at the Q1 Virtual Investor Summit. The conference will take place on March 23-25, 2021, and includes a Nephros company presentation and Q&A at 2:30 p.m. ET on March 23.

Nephros to Present at the Q1 Virtual Investor Summit

SOUTH ORANGE, NJ, March 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire --  Nephros , Inc. (Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced that Andy Astor, Chief Executive Officer, has been invited to present at the  Inaugural Emerging Growth Virtual Conference ,  presented by M-Vest LLC and Maxim Group LLC. The conference will take place on March 17th and 18th from 9:00 am-5:00 pm EST, featuring roundtable discussions with C-suite executives moderated by Maxim Research Analysts, fireside chats with live Q&A, and presentations from hundreds of issuers both domestically and internationally.

Nephros to Participate in M-Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

Nephros Inc. (NEPH) delivered earnings and revenue surprises of 33.33% and 1.92%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Nephros Inc. (NEPH) Reports Q4 Loss, Tops Revenue Estimates

Nephros, Inc. (NEPH) CEO Andy Astor on Q4 2020 Results - Earnings Call Transcript

Shares of Nephros (NASDAQ:NEPH) were flat after the company reported Q4 results. Quarterly Results Earnings per share fell 300.00% over the past year to ($0.08), which beat the estimate of ($0.11).

Recap: Nephros Q4 Earnings

Fourth Quarter Net Revenue $2.3 Million, Up 10% Sequentially Over Third Quarter Full Year Revenue $8.6 million, Down 17% Against Prior Year

Nephros Reports 2020 Fourth Quarter and Full Year Financial Results

SOUTH ORANGE, NJ, Feb. 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nephros , Inc. (Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced that it will file its fourth quarter and full year 2020 financial results on Monday, March 1, 2021 after market close and will host a conference call that same day at 4:30 PM ET, during which management will discuss the company's financial results and provide a general business overview.

Nephros Announces Fourth Quarter and Full Year 2020 Financial Results Conference Call

Nephros Inc. (NEPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Nephros Inc. (NEPH) Q4 Earnings Expected to Decline

SOUTH ORANGE, NJ, Feb. 18, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nephros , Inc. (Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced the appointment of Wes Lobo as Chief Marketing Officer, reporting directly to Nephros Chief Executive Officer, Andy Astor. In this role, Wes will be responsible for driving the company's strategic growth through innovative solutions, go-to-market strategies, and marketing.

Nephros Hires Wes Lobo as Chief Marketing Officer

Anticipates $2.3 Million Revenue in Fourth Quarter, $8.5 Million in Full-Year; Quarterly Revenue Grew 9% Sequentially Over Third Quarter; Full Year Revenue Declined 17%

Nephros Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2020

HDF Assist Device Complete; Special 510(k) to be Filed in Early 2021

Update: Nephros Provides Year-End Technology Update, Including HDF Program Status

Nephros Provides Year-End Technology Update, Including HDF Program Status

In this article we will check out the progression of hedge fund sentiment towards Nephros, Inc. (NASDAQ:NEPH) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 payment structure, hedge funds have more incentives and resources than the average investor. The funds have access to expert networks and get tips from industry insiders. They also employ numerous Ivy League graduates and MBAs. Like everyone else, hedge funds perform miserably at times, but their consensus picks have historically outperformed the market after risk adjustments.

Where Do Hedge Funds Stand On Nephros, Inc. (NEPH)?

SOUTH ORANGE, NJ, Nov. 09, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire --Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced that it will participate at the following investor conferences in November.

Nephros to Present at Three November Investment Conferences

Nephros, Inc.'s (NEPH) CEO Andy Astor on Q3 2020 Results - Earnings Call Transcript

Finance Veteran Strengthens Management Team; Quarter-over-Quarter Net Revenue up 34%; Year-over-Year down 31%

Nephros Appoints Dan D'Agostino as CFO and Reports Third Quarter Financial Results

SOUTH ORANGE, NJ, Oct. 29, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire  -- Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced that it will file its third quarter 2020 financial results on Thursday, November 5, 2020 after market close and will host a conference call that same day at 4:30 PM ET, during which management will discuss the company's financial results and provide a general business overview.

Nephros Announces Third Quarter 2020 Financial Results Conference Call

SOUTH ORANGE, NJ, Oct. 16, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nephros, Inc. (Nasdaq: NEPH) (“Nephros” or the “Company”), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical device and commercial markets, today announced the pricing of a registered direct offering of 833,333 shares of common stock at a price to the public of $6.00 per share.  The offering is expected to close on or about October 20, 2020, subject to the satisfaction of customary closing conditions.

Nephros Announces Pricing of $5 Million Registered Direct Offering of Common Stock

SOUTH ORANGE, NJ, Oct. 13, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire --  Nephros , Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced availability of DialyPath™, an assay that estimates endotoxin levels in dialysis water samples.

News for Nephros Inc Stock (NEPH)